The present invention relates to a pharmaceutical composition intended for the treatment of a viral infection by influenza virus type a in a subject, which composition comprises a compound having the property of acting as an inhibitor of the fixing of the viral rna to the nucleoprotein of the influenza virus type a, said compound having the property of binding to the field of connection of the viral rna in the nucleoprotein. The present invention also relates to a pharmaceutical composition intended for the treatment of a viral infection by a orthomyxovirus in a subject, which composition comprises a compound having the property of acting as an inhibitor of the fixing of the viral rna to the nucleoprotein of orthomyxovirus, said compound having the property of binding to the field of connection of the viral rna in the nucleoprotein of the virus. The present invention also carries, on a compound having the property of acting as an inhibitor of the fixing of the viral rna to the nucleoprotein of the influenza virus type a, said compound having the property of binding to the field of connection of the viral rna in the nucleoprotein of the influenza virus type a and to a method of identification of a compound having the property of binding at the level of the field of connection of the viral rna in the nucleoprotein of the influenza virus type a.Linvention porte sur une composition pharmaceutique destinée au traitement dune infection virale par un virus Influenza de type A chez un sujet, laquelle composition comprend un composé ayant la propriété dagir en tant quinhibiteur de la fixation de lARN viral à la nucléoprotéine des virus Influenza de type A, ledit composé ayant la propriété de se lier au domaine de liaison de lARN viral sur ladite nucléoprotéine. Linvention porte également sur une composition pharmaceutique destinée au traitement dune infection virale par un Orthomyxovirus chez un sujet, laquelle composition comprend un composé ayant la propriété dagir en tant
